GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

WGS 01.09.2025

Full Press ReleaseSEC FilingsOur WGS Tweets

About Gravity Analytica

Recent News

  • 01.17.2025 - GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • 01.13.2025 - GeneDx Announces Preliminary 2024 Financial Results
  • 01.09.2025 - GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers

Recent Filings

  • 01.16.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - 8-K Current report
  • 01.13.2025 - 3 Initial statement of beneficial ownership of securities

STAMFORD, Conn.--(BUSINESS WIRE)--Jan. 9, 2025--GeneDx(Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today announced anew wayto provide genetic counseling and test-ordering services for patients and families seeking access to genetic testing. The new telehealth testing pathway aims to shorten the diagnostic odyssey by connecting parents directly with genetic experts, increasing access to exome and genome testing.

Despite mounting clinical evidence for the benefits of exome testing in delivering a definitive diagnosis for rare disease patients, many individuals face barriers to access comprehensive genetic testing. The average time to an accurate diagnosis remains approximately 4-5 years, and in some populations, it can extend up to a decade.1At the same time, a child with neurodevelopmental disorders is likely to accrue over$10,000in additional health costs and undergo more than 5 uninformative tests.2Every day that a child with a rare disease waits for a genetic diagnosis, their families lose the opportunity for disease-specific care plans, better resources, and the positive psychological impacts of improved understanding and support. Currently, the system presents significant challenges for parents seeking answers for their children’s unexplained symptoms, with wait times for medical genetics and developmental/behavioral pediatricians increasing significantly over the past three years.3

“GeneDx understands that a genetic diagnosis can be life-changing for families, offering crucial insights that inform personalized care and treatment, which can lead to significantly improved health outcomes, including gene therapies and proactive condition management,” said Dr.Paul Kruszka, MD, FACMG, Chief Medical Officer atGeneDx. “GeneDx is steadfast in our commitment to increasing access to exome and genome testing by responsibly removing the systematic barriers that have previously prevented patients and families from accessing this critical testing.”

Too many children experience symptoms without a clear answer as to why. Meanwhile, genetic tests exist that may provide the answers these families desperately need. To bridge that gap,GeneDxis working with a leading telehealth genetics provider, to enable an easier way for parents to access actionable, accurate genetic testing for their child by streamlining the referral process to better support patients and families in need of exome testing. Parents can schedule testing, appointments, and receive a diagnosis in as soon as five weeks by visitingGeneDx.com/get-exome.

GeneDx'scommitment to expanding access to testing extends beyond enabling new channels and focuses on ensuring all patients have equitable access to care.Recent findingshighlight that racial disparities in delivering precise genetic diagnoses are due to limited access to testing, not differences in diagnostic yield across diverse populations. By expanding access toGeneDx'sexome and genome testing, more patients can benefit from the genomic insights of over 700,000 exomes and genomes, increasing the likelihood of obtaining definitive diagnoses.

AboutGeneDx

AtGeneDx(Nasdaq: WGS), we believe that everyone deserves personalized, targeted medical care—and that it all begins with a genetic diagnosis. Fueled by one of the world’s largest rare disease data sets, our industry-leading exome and genome tests translate complex genomic data into clinical answers that unlock personalized health plans, accelerate drug discovery, and improve health system efficiencies. For more information, please visitgenedx.comand connect with us onLinkedIn,X,Facebook, andInstagram.

References:

  1. Marwaha S, Knowles JW, and Ashley EA. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. Genome Med. 2022 Feb 28;14(1):23. doi: 10.1186/s13073-022-01026-w.
  2. Soden SE, Saunders CJ, Willig LK, et al. Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med. 2014Dec 3;6(265):265ra168. doi: 10.1126/scitranslmed.3010076.
  3. Klima, T. (2023). Access to Pediatric Specialty Care inCalifornia: Results of The Children’sSpecialty Care Coalition2022Member Survey(pp. 1–11).California: Practical Research Solutions.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20250109387267/en/

Investor Relations Contact:Investors@GeneDx.comMedia Contact:Press@GeneDx.com

Source:GeneDx

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com